Wednesday, 14 November 2012

Drug Patent Expirations for the week of November 11, 2012


Drug Patent Expirations for the week of November 11, 2012

TradenameApplicantGeneric NamePatent NumberPatent Expiration
ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,399,632*PEDNov 11, 2012
ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,399,632*PEDNov 11, 2012
ALLEGRASanofi Aventis Usfexofenadine hydrochloride6,399,632*PEDNov 11, 2012
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride6,187,791*PEDNov 11, 2012
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,187,791*PEDNov 11, 2012
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride6,399,632*PEDNov 11, 2012
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,399,632*PEDNov 11, 2012
ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,187,791*PEDNov 11, 2012
ALLEGRASanofi Aventis Usfexofenadine hydrochloride6,187,791*PEDNov 11, 2012
ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,187,791*PEDNov 11, 2012
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,399,632*PEDNov 11, 2012
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride6,399,632*PEDNov 11, 2012
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,187,791*PEDNov 11, 2012
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTIONSanofi Aventis Usfexofenadine hydrochloride; pseudoephedrine hydrochloride6,187,791*PEDNov 11, 2012
RAPAFLOWatson Labssilodosin5,403,847Nov 13, 2012
RAPAFLOWatson Labssilodosin6,015,819Nov 13, 2012
RAPAFLOWatson Labssilodosin5,780,485Nov 13, 2012
PEPCID COMPLETEMcneil Conscalcium carbonate; famotidine; magnesium hydroxide5,229,137*PEDNov 16, 2012
SURFAXINDiscovery Labslucinactant5,407,914Nov 17, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)